Adding Irinotecan Fails to Improve Recurrence-Free Survival in High-Risk Colon Cancer
A 795-patient trial found no recurrence-free survival benefit from adding irinotecan after surgery for high-risk stage III colon cancer.
Summary
More intensive chemotherapy after surgery did not improve recurrence-free survival in high-risk stage III colon cancer. The phase III IROCAS trial compared standard chemotherapy with a regimen that added irinotecan in 795 patients. After three years, 65.6% receiving intensified treatment were alive without cancer recurrence, compared with 66.3% receiving standard treatment. Overall survival was numerically higher with intensified treatment, but the difference was not statistically significant, and follow-up remains insufficient for firm conclusions about survival. Patients generally received substantial treatment doses, making inadequate drug delivery an unlikely explanation for the findings. The results do not support routinely adding irinotecan in this setting. They also highlight a distinction: identifying a cancer as high risk does not reveal which additional treatment will help. Ongoing trials may clarify whether selected patient groups benefit.
Detailed Summary
High-risk stage III colon cancer can return even after surgery and chemotherapy. Researchers tested whether adding another chemotherapy drug could improve outcomes for patients whose tumors had spread extensively to nearby lymph nodes or grown through the bowel wall. The findings suggest that more intensive treatment does not necessarily provide better protection against recurrence.
The phase III IROCAS trial enrolled 795 patients with completely removed cancers at 93 centers in France, Canada, and Italy. Their median age was 59 years, and 40% were women. Researchers compared modified FOLFIRINOX, which includes irinotecan, with standard modified FOLFOX6 chemotherapy. Both regimens included oxaliplatin, fluorouracil, and leucovorin. The key outcome was survival without cancer recurrence or death.
At three years, 65.6% of patients receiving intensified treatment were alive without recurrence, compared with 66.3% receiving standard treatment. This difference was not statistically significant. Overall survival was 91.2% versus 86.7%, respectively, but that difference was also not statistically significant. Overall survival results remain immature, so the numerical gap cannot establish a survival benefit.
Treatment delivery did not appear to explain the negative result: patients received substantial irinotecan dosing, and oxaliplatin exposure was comparable between groups. The broader lesson is that tumor features that identify high recurrence risk do not necessarily identify patients who benefit from adding another drug. Researchers highlighted the need for better ways to match treatments to individual cancers.
For clinical practice, these results do not support routinely adding irinotecan after surgery for this patient group. Patients should discuss established options and appropriate trials with their oncology team rather than assume stronger chemotherapy is better. Important caveats include incomplete survival follow-up, missing safety details in the supplied excerpt, and pending trials that could identify different results in selected populations. The findings concern this specific postoperative setting and should not be generalized to all colorectal cancers.
Key Findings
- Three-year recurrence-free survival was 65.6% with intensified chemotherapy versus 66.3% with standard treatment, showing no statistically significant improvement.
- The trial enrolled 795 patients with completely removed, high-risk stage III colon cancer; median age was 59 years.
- Overall survival differences were not statistically significant, and longer follow-up is needed before drawing firm survival conclusions.
- Results do not support routinely adding irinotecan after surgery in this setting; discuss established options and clinical trials with an oncologist.
Methodology
This MedPage Today meeting report summarizes the phase III IROCAS trial presented at the European Society for Medical Oncology congress and reportedly published in Annals of Oncology. Its evidence basis is a large, multicenter treatment comparison, with numerical results and independent expert commentary, but this assessment relies on the supplied news excerpt rather than the primary publication.
Study Limitations
The supplied article ends mid-sentence and does not provide full safety results, follow-up duration, or detailed subgroup analyses. Overall survival remains immature, and a nonsignificant result does not prove the regimens are equivalent; the primary publication should be checked for complete methods and outcomes.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: